WO2015114655A2 - Modified release tablet of pregabalin - Google Patents

Modified release tablet of pregabalin Download PDF

Info

Publication number
WO2015114655A2
WO2015114655A2 PCT/IN2015/000032 IN2015000032W WO2015114655A2 WO 2015114655 A2 WO2015114655 A2 WO 2015114655A2 IN 2015000032 W IN2015000032 W IN 2015000032W WO 2015114655 A2 WO2015114655 A2 WO 2015114655A2
Authority
WO
WIPO (PCT)
Prior art keywords
modified release
release tablet
pregabalin
tablet according
pharmaceutically acceptable
Prior art date
Application number
PCT/IN2015/000032
Other languages
French (fr)
Other versions
WO2015114655A3 (en
Inventor
Nilesh Patel
Umesh Setty
Ashish Sehgal
Original Assignee
Intas Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Limited filed Critical Intas Pharmaceuticals Limited
Publication of WO2015114655A2 publication Critical patent/WO2015114655A2/en
Publication of WO2015114655A3 publication Critical patent/WO2015114655A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach. Further it relates to a process for the preparation of the modified release tablet.
  • Pregabalin is an analogue of the physiologically important endogenous neurotransmitter [gamma] -amino butyric acid (GABA), which is involved in the regulation of neural processes.
  • GABA neurotransmitter
  • the lUPAC name of pregabalin [.INN] is (S)-3-(aminomethyl)-5-methyl hexanoic acid.
  • the chemical structure of pregabal in is shown in formula below:
  • Pregabalin is disclosed in U.S. Patent Nos. 6,197,819 and 5,563,175, which describe its use in the treatment of seizure disorders.
  • U.S. Patent No. 6,1 17,906 discloses the use of pregabalin in treating anxiety, while U.S. Patent No. 6,001 ,876 discloses its use in treating pain.
  • pregabalin is available as conventional immediate-release capsules marketed by CP Pharms/Pfizer under the brand name Lyrica ® .
  • Lyrica ® Capsules requires two or three times a day dosing.
  • a once-daily tablet is desirable.
  • pregabalin cannot be absorbed in the entire gastrointestinal tract (GIT).
  • GIT gastrointestinal tract
  • Pregabalin is only absorbed in the upper sections of the gut. It is therefore desirable to have a dosage form which has a longer retention time in the upper GIT and which, during that time, releases the active agent continuously over a longer period of time.
  • the U.S. Publication Application No. 2007/026951 1 discloses a pregabalin formulation containing matrix forming agent and a swelling agent, wherein the matrix forming agent is polyvinyl acetate and polyvinylpyrrolidone, and the swelling agent is cross-linked polyvinylpyrrolidone.
  • the U.S. Publication Application No. 2010/0255067 describes pharmaceutical compositions comprising pregabalin, a hydrophobic release controlling agent, and other pharmaceutically acceptable excipients.
  • the U.S. Publication Application No. 2013/149253 describes oral dosage form for the modified release of pregabalin, comprising pregabalin in a matrix comprising a swelling agent, a matrix former and a buoyancy agent or alternatively a sedimentation agent. Therefore, a modified release tablet that retains in the upper parts of the gastrointestinal tract would be an ideal dosage form for pregabalin.
  • the objective of the present invention is to develop a modified release tablet of pregabalin.
  • the primary object of the invention is to provide a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
  • Another object of the invention is to provide a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
  • Another object of the invention is to provide a process for the preparation of a modified release tablet of pregabalin.
  • the invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drag is released into the stomach.
  • the invention in another embodiment, relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
  • the invention relates to a modified release tablet comprising pregabalin with colloidal silicon dioxide as a low-density excipient, croscarmellose sodium as swelling agent and hydroxy ethyl cellulose (HEC) as gelling agent.
  • colloidal silicon dioxide as a low-density excipient
  • croscarmellose sodium as swelling agent
  • HEC hydroxy ethyl cellulose
  • the invention relates to a modified release tablet comprising pregabalin with ethyl cellulose (EC 20 cps) as a low-density excipient, sodium starch glycolate as swelling agent, polyvinyl pyrrolidone (PVP) as gelling agent, and additionally a bubble-generating mixture.
  • EC 20 cps ethyl cellulose
  • PVP polyvinyl pyrrolidone
  • the invention relates to a process for the preparation of a modified release tablet of pregabalin, preferably direct compression method.
  • the present invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
  • the "modified release tablet” remains in the patient's stomach following oral administration, which is substantially longer than the average residence time of a corresponding immediate release dosage form.
  • hydrodynamic balance for the purpose of the invention means that the tablet maintains its balance within the stomach such that it does not sink or passes away through the pylorus, but the tablet remains suspended on the surface of the gastric fluid during which the drug is released into the stomach.
  • the term "physical integrity" for the purpose of the invention refers to the tablet strength that maintains the tablet structure in an intact form and thus it does not rupture into smaller units, during which the drug is released into the stomach.
  • the present invention may employ any pharmaceutically acceptable form of pregabalin, including its free form (zwitter ion), and its pharmaceutically acceptable complexes, acid addition salts, base .
  • addition salts solvates, hydrates, and polymorphs.
  • the present invention relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
  • the "low-density excipient" of the present invention includes microcrystalline cellulose (MCC) PH 105 grade, colloidal silicon dioxide (commonly known as Aerosil 200), ethyl cellulose (EC 20 cps) or combinations or copolymers thereof.
  • the excipient MCC PH 105 grade here refers to micro crystalline cellulose having mean particle size of 20 microns and bulk density of 0.2 to 0.3 gm/cc.
  • excipient Aerosil ⁇ grade here refers to colloidal silicon dioxide having mean particle size of 12-16 nm and tapped density of 0.05gm/cc.
  • the excipient EC 20 cps grade here refers to ethyl cellulose having mean particle size of 5-60 microns and bulk density of 0.2gm/cc.
  • the "swelling agent" of the present invention includes croscarmellose sodium, sodium starch glycolate (SSG), microcrystalline. cellulose (MCC), starch, cross- linked homopolymers of l-vinyl-pyrrolidin-2-one (Crospovidone) or combinations or copolymers thereof.
  • the swelling agent absorbs water from the gastric fluid and thereby the tablet expands in size larger than the pylorus.
  • the swelling agent is generally used in an amount ranging from about 5% to about 30% by weight of the tablet composition.
  • the "gelling agent" of the present invention includes polyvinyl pyrrolidone (PVP), polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol such as carbomers (carbopols), alginates, preferably sodium alginate, hydroxyalkyl cellulose, especially hydroxyethyl cellulose (HEC), xanthan gum or combinations or copolymers thereof.
  • PVP polyvinyl pyrrolidone
  • carbomers carbomers
  • alginates preferably sodium alginate
  • hydroxyalkyl cellulose especially hydroxyethyl cellulose (HEC), xanthan gum or combinations or copolymers thereof.
  • the gelling agent includes excipient that forms a gel when in contact with gastric fluid and thereby modifies the drug release characteristics of the tablet.
  • the gelling agent is generally used in an amount ranging from about 0.5% to about 40% by weight of the tablet composition.
  • the "bubble-generating mixture" of the present invention includes, non-limiting examples, such as bicarbonate/ascorbic acid, bicarbonate/tartaric acid, bicarbonate/citric acid, carbon ate/tartaric acid, carbonate/citric acid and/or carbonate/ascorbic acid.
  • the modified release tablet of the present invention when comes in contact with gastric fluid it readily forms bubbles that get entrapped within the well-defined tablet structure such that the tablet maintains its hydrodynamic balance and physical integrity for the time period during which pregabalin is released into the stomach.
  • the modified release tablet may also comprise further pharmaceutically acceptable excipients such as diluents, binders, rate-controlling agents, lubricants, wetting agent, glidants and coating excipients.
  • excipients such as diluents, binders, rate-controlling agents, lubricants, wetting agent, glidants and coating excipients.
  • the present invention may employ the rate controlling agents, preferably hydroxy propyl methyl cellulose (HPMC) or other pharmaceutically acceptable excipients.
  • rate controlling agents preferably hydroxy propyl methyl cellulose (HPMC) or other pharmaceutically acceptable excipients.
  • the modified release tablet of pregabalin is designed for once-daily administration and achieves bioequivalence with immediate release dosage form of pregabalin that is taken two- or three-times daily.
  • the invention in another embodiment, relates to a process for the preparation of a modified release tablet of pregabalin. It can be prepared by routine tableting method including direct compression, granulation and pelletization methods. Preferably, the process for the preparation is direct compression method.
  • Example 1 Modified Release Tablet of Pregabalin.
  • the modified release tablet of the present invention is prepared by Direct Compression method in the procedural steps as described below.

Abstract

The present invention relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent and at least one gelling agent, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.

Description

FIELD OF THE INVENTION
The present invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach. Further it relates to a process for the preparation of the modified release tablet.
BACKGROUND OF THE INVENTION
Pregabalin is an analogue of the physiologically important endogenous neurotransmitter [gamma] -amino butyric acid (GABA), which is involved in the regulation of neural processes. The lUPAC name of pregabalin [.INN] is (S)-3-(aminomethyl)-5-methyl hexanoic acid. The chemical structure of pregabal in is shown in formula below:
¾N
O
Pregabalin is disclosed in U.S. Patent Nos. 6,197,819 and 5,563,175, which describe its use in the treatment of seizure disorders. U.S. Patent No. 6,1 17,906 discloses the use of pregabalin in treating anxiety, while U.S. Patent No. 6,001 ,876 discloses its use in treating pain. Currently, pregabalin is available as conventional immediate-release capsules marketed by CP Pharms/Pfizer under the brand name Lyrica®. The marketed product Lyrica® Capsules requires two or three times a day dosing. In order to improve patient compliance and to reduce the severity and frequency of side effects by reducing peak blood levels along with an increase in drug efficacy by increasing minimum plasma concentration, a once-daily tablet is desirable.
However, the development of a suitable once-daily formulation is rendered more difficult by the fact that pregabalin cannot be absorbed in the entire gastrointestinal tract (GIT). Pregabalin is only absorbed in the upper sections of the gut. It is therefore desirable to have a dosage form which has a longer retention time in the upper GIT and which, during that time, releases the active agent continuously over a longer period of time.
■'
The U.S. Publication Application No. 2007/026951 1 discloses a pregabalin formulation containing matrix forming agent and a swelling agent, wherein the matrix forming agent is polyvinyl acetate and polyvinylpyrrolidone, and the swelling agent is cross-linked polyvinylpyrrolidone.
■
The U.S. Publication Application No. 2010/0255067 describes pharmaceutical compositions comprising pregabalin, a hydrophobic release controlling agent, and other pharmaceutically acceptable excipients. The U.S. Publication Application No. 2013/149253 describes oral dosage form for the modified release of pregabalin, comprising pregabalin in a matrix comprising a swelling agent, a matrix former and a buoyancy agent or alternatively a sedimentation agent. Therefore, a modified release tablet that retains in the upper parts of the gastrointestinal tract would be an ideal dosage form for pregabalin. The objective of the present invention is to develop a modified release tablet of pregabalin.
OBJECTS OF THE INVENTION
The primary object of the invention is to provide a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
Another object of the invention is to provide a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
Another object of the invention is to provide a process for the preparation of a modified release tablet of pregabalin.
SUMMARY OF THE INVENTION
In a first embodiment, the invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drag is released into the stomach.
In another embodiment, the invention relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
In a preferred embodiment, the invention relates to a modified release tablet comprising pregabalin with colloidal silicon dioxide as a low-density excipient, croscarmellose sodium as swelling agent and hydroxy ethyl cellulose (HEC) as gelling agent.
In a preferred embodiment, the invention relates to a modified release tablet comprising pregabalin with ethyl cellulose (EC 20 cps) as a low-density excipient, sodium starch glycolate as swelling agent, polyvinyl pyrrolidone (PVP) as gelling agent, and additionally a bubble-generating mixture.
In another embodiment, the invention relates to a process for the preparation of a modified release tablet of pregabalin, preferably direct compression method.
DETAILED DESCRIPTION
The present invention relates to a modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
The "modified release tablet" remains in the patient's stomach following oral administration, which is substantially longer than the average residence time of a corresponding immediate release dosage form.
Not bound to any theory, the term "hydrodynamic balance" for the purpose of the invention means that the tablet maintains its balance within the stomach such that it does not sink or passes away through the pylorus, but the tablet remains suspended on the surface of the gastric fluid during which the drug is released into the stomach.
Not bound to any theory, the term "physical integrity" for the purpose of the invention refers to the tablet strength that maintains the tablet structure in an intact form and thus it does not rupture into smaller units, during which the drug is released into the stomach.
The present invention may employ any pharmaceutically acceptable form of pregabalin, including its free form (zwitter ion), and its pharmaceutically acceptable complexes, acid addition salts, base . addition salts solvates, hydrates, and polymorphs.
The present invention relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble-generating mixture, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach. The "low-density excipient" of the present invention includes microcrystalline cellulose (MCC) PH 105 grade, colloidal silicon dioxide (commonly known as Aerosil 200), ethyl cellulose (EC 20 cps) or combinations or copolymers thereof.
The excipient MCC PH 105 grade here refers to micro crystalline cellulose having mean particle size of 20 microns and bulk density of 0.2 to 0.3 gm/cc.
The excipient Aerosil ΖΌΌ grade here refers to colloidal silicon dioxide having mean particle size of 12-16 nm and tapped density of 0.05gm/cc.
The excipient EC 20 cps grade here refers to ethyl cellulose having mean particle size of 5-60 microns and bulk density of 0.2gm/cc.
The "swelling agent" of the present invention includes croscarmellose sodium, sodium starch glycolate (SSG), microcrystalline. cellulose (MCC), starch, cross- linked homopolymers of l-vinyl-pyrrolidin-2-one (Crospovidone) or combinations or copolymers thereof.
The swelling agent absorbs water from the gastric fluid and thereby the tablet expands in size larger than the pylorus. The swelling agent is generally used in an amount ranging from about 5% to about 30% by weight of the tablet composition.
The "gelling agent" of the present invention includes polyvinyl pyrrolidone (PVP), polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol such as carbomers (carbopols), alginates, preferably sodium alginate, hydroxyalkyl cellulose, especially hydroxyethyl cellulose (HEC), xanthan gum or combinations or copolymers thereof. The gelling agent includes excipient that forms a gel when in contact with gastric fluid and thereby modifies the drug release characteristics of the tablet. The gelling agent is generally used in an amount ranging from about 0.5% to about 40% by weight of the tablet composition.
The "bubble-generating mixture" of the present invention includes, non-limiting examples, such as bicarbonate/ascorbic acid, bicarbonate/tartaric acid, bicarbonate/citric acid, carbon ate/tartaric acid, carbonate/citric acid and/or carbonate/ascorbic acid.
The modified release tablet of the present invention when comes in contact with gastric fluid it readily forms bubbles that get entrapped within the well-defined tablet structure such that the tablet maintains its hydrodynamic balance and physical integrity for the time period during which pregabalin is released into the stomach.
In addition to the above-mentioned ingredients, the modified release tablet may also comprise further pharmaceutically acceptable excipients such as diluents, binders, rate-controlling agents, lubricants, wetting agent, glidants and coating excipients.
The present invention may employ the rate controlling agents, preferably hydroxy propyl methyl cellulose (HPMC) or other pharmaceutically acceptable excipients.
The modified release tablet of pregabalin is designed for once-daily administration and achieves bioequivalence with immediate release dosage form of pregabalin that is taken two- or three-times daily.
In another embodiment, the invention relates to a process for the preparation of a modified release tablet of pregabalin. It can be prepared by routine tableting method including direct compression, granulation and pelletization methods. Preferably, the process for the preparation is direct compression method.
In order to further illustrate the present invention, the following examples are provided for the purpose of clarity of understanding. However, it is not intended in any way to limit the scope of present invention and it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the scope of the invention.
Example 1: Modified Release Tablet of Pregabalin.
Figure imgf000009_0001
The modified release tablet of the present invention is prepared by Direct Compression method in the procedural steps as described below.
Manufacturing Process:
(i) Sift all ingredients through appropriate sieves,
(ii) Blend the sifted ingredients for an appropriate time,
(iii) Compressed the blend into tablets
(iv) Optionally film coat the compressed tablets.
Dissolution Studies of Modified release tablet formulation (F3) as representative example:
Figure imgf000010_0001

Claims

We claim:
1. A modified release tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during which the drug is released into the stomach.
2. The modified release tablet according to claim 1, wherein the modified release tablet comprises pregabalin with at least one low-density excipient, at least one swelling agent, at least one gelling agent, and optionally a bubble- generating mixture.
3. The modified release tablet according to claim 2, wherein the low-density excipient is selected from the group of microcrystalline cellulose (MCC), colloidal silicon dioxide (Aerosil 200), ethyl cellulose (EC 20 cps) or combinations or copolymers thereof.
4. The modified release tablet according to claim 2, wherein the swelling agent is selected from the group of croscarmellose sodium, sodium starch glycolate (SSG), microcrystalline cellulose (MCC), starch, cross-linked homopolymers of l-vinyl-pyrrolidin-2-one (Crospovidone) or combinations or copolymers thereof.
5. The modified release tablet according to claim 2, wherein the gelling agent is selected from the group of polyvinyl pyrrolidone (PVP), Polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol such as carbomers (carbopols), alginates, hydroxy alkyl cellulose, Xanthan gum or combinations or copolymers thereof.
6. The modified release tablet according to claim 2, wherein the bubble forming mixture is selected from the group of bicarbonate/ascorbic acid, bicarbonate/tartaric acid, bicarbonate/citric acid, carbonate/tartaric acid, carbonate/citric acid and/or carbonate/ascorbic acid.
7. The modified release tablet according to claim 1 , wherein the modified release tablet is a once-daily administration and achieves bioequivalence with immediate release dosage form of pregabalin that is taken two- or three-times daily.
8. The modified release tablet according to claim 1 , wherein the modified release tablet is prepared by direct compression method.
9. The modified release tablet according to claim 1, wherein the modified release tablet comprises pregabalin, colloidal silicon dioxide, croscarmellose sodium, hydroxy ethyl cellulose (HEC), and optionally other pharmaceutically acceptable excipients.
10. The modified release tablet according to claim 1, wherein the modified release tablet comprises pregabalin, ethyl cellulose, sodium starch glycolate, polyvinyl pyrrolidone (PVP) and optionally other pharmaceutically acceptable excipients.
PCT/IN2015/000032 2014-01-21 2015-01-20 Modified release tablet of pregabalin WO2015114655A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN198/MUM/2014 2014-01-21
IN198MU2014 IN2014MU00198A (en) 2014-01-21 2015-01-20

Publications (2)

Publication Number Publication Date
WO2015114655A2 true WO2015114655A2 (en) 2015-08-06
WO2015114655A3 WO2015114655A3 (en) 2016-01-28

Family

ID=53757862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000032 WO2015114655A2 (en) 2014-01-21 2015-01-20 Modified release tablet of pregabalin

Country Status (2)

Country Link
IN (1) IN2014MU00198A (en)
WO (1) WO2015114655A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106606495A (en) * 2015-10-27 2017-05-03 四川海思科制药有限公司 Pregabalin sustained-release tablet medicinal composition and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000281C2 (en) * 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
WO2009066325A1 (en) * 2007-11-23 2009-05-28 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
EP2415460A1 (en) * 2010-08-03 2012-02-08 ratiopharm GmbH Formulations of pregabalin for oral administration
WO2012035559A2 (en) * 2010-09-17 2012-03-22 Panacea Biotec Ltd Sustained release pharmaceutical compositions comprising pregabalin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106606495A (en) * 2015-10-27 2017-05-03 四川海思科制药有限公司 Pregabalin sustained-release tablet medicinal composition and preparation method thereof

Also Published As

Publication number Publication date
WO2015114655A3 (en) 2016-01-28
IN2014MU00198A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
WO2008006528A2 (en) Pharmaceutical compositions comprising levetiracetam
US20220249491A1 (en) Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
JP2011504491A (en) Controlled release pharmaceutical composition of pregabalin
US9393205B2 (en) Gastroretentive tablets
KR20060132891A (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
JPH02209A (en) Control release compound of carbidopa/levodopa
US20130149253A1 (en) Oral dosage form of pregabalin
WO2010103544A2 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
TW201906608A (en) Oral solid preparation
JP5300262B2 (en) Sustained release formulation for oral administration of metformin
WO2016062182A1 (en) Pregabalin sustained-release preparation
EP3518910A1 (en) Compositions of midodrine and methods of using the same
WO2014209087A1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
US20200170999A1 (en) Apremilast sustained release preparation
WO2012020301A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2013114281A1 (en) Pregabalin gr tablets
WO2015114655A2 (en) Modified release tablet of pregabalin
WO2015114656A2 (en) Mucoadhesive tablet of pregabalin
EP2801350B1 (en) Pharmaceutical Formulations of Lacosamide
WO2009087675A2 (en) Novel coated extended release pharmaceutical compositions of levetiracetam
CN114246836B (en) Pregabalin sustained release tablet and preparation method thereof
US10688050B1 (en) Pharmaceutical composition comprising ibrutinib
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen
JP2023534548A (en) Sustained-release pharmaceutical preparations of condensed tricyclic amino acid derivatives and methods for preparing them
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15743287

Country of ref document: EP

Kind code of ref document: A2